To the Editor: We have read with interest many of the articles concerning West Nile virus (WNV) published in the July 2003 issue of Emerging Infectious Diseases. Last summer Ohio was one of the leading states with WNV infection in humans. Consequently, requests for tests for this pathogen have increased. Unfortunately, the turnaround time for testing these specimens may be delayed because of shipping difficulties secondary to associates, the limited number of laboratories that can perform these assays, and an increase in requests at testing facilities.
Cytologic examination of cerebrospinal fluid (CSF) from patients with WNV has not been studied. Although cytologic examination of CSF from patients with encephalitis is likely nonspecific, it may provide supportive information of the suspected disease process, and is useful for excluding other conditions, such as neoplasia. Of the 22 patients that were hospitalized at our institution last year with WNV meningoencephalitis, documented by serologic tests and/or reverse transcription-polymerase chain reaction, CSF of 4 of these patients was submitted for cytologic examination. Of these 4, 3 had a sufficient number of cells in the CSF specimen (47, 213, and 495 cell/μL) to afford cytologic examination, whereas one had a paucicellular CSF, with only 2 white blood cells/μl. The cytologic features from the 3 patients >10 cells/μL consistently demonstrated a mixture of lymphocytes at various stages of activation and occasional large monocytic-like cells with cerebriform nuclei reminiscent of the Mollaret cells described in CSF of patients with recurrent meningitis (Figure) (1).
Figure
Three Mollaret-like cells are present (center), with a neutrophil (upper left) and a lymphocyte (upper right) in cerebrospinal fluid from a patient with West Nile Virus encephalitis, confirmed by reverse transcription–polymerase chain reaction ...
Mollaret described cells with enlarged nuclei and cerebreform nuclear contours in CSF of patients with recurrent, aseptic meningitis (1). Although he believed these were of endothelial origin, immunohistochemical studies have subsequently shown that they are monocytes (2). This type of meningitis, now commonly known as Mollarets meningitis, has been associated with herpes simplex virus encephalitis, but the definitive cause of all cases remains unclear (3).
One of the patients infected with WNV meningoencephalitis who had Mollaret-like cells in CSF died. Postmortem neuropathologic examination showed an extensive perivascular lymphocytic infiltrate which contained mononuclear cells consistent with the Mollaret-like cells in CSF. These mononuclear cells were stained with an immunohistochemical stain directed against the CD68 antigen, which supports a monocytic origin (4). Further studies are needed to delineate the consistency of Mollaret-like cells in CSF of patients with WNV meningoencephalitis. Finding Mollaret-like cells admixed with activated lymphocytes may be a useful, readily-available test that provides supportive evidence of viral encephalitis in the appropriate clinical setting, until more definitive tests are available.
[1]
G. Stoppe,et al.
Mollaret's meningitis: CSF-immunocytological examinations
,
1987,
Journal of Neurology.
[2]
R. Prayson,et al.
The Neuropathology of West Nile Virus Meningoencephalitis
,
2003
.
[3]
D. García de Viedma,et al.
Rapid detection of resistance in Mycobacterium tuberculosis: a review discussing molecular approaches
,
2003
.
[4]
R. Prayson,et al.
The neuropathology of West Nile virus meningoencephalitis. A report of two cases and review of the literature.
,
2003,
American journal of clinical pathology.
[5]
G. Orefici,et al.
Surveillance of anti-tuberculosis drug resistance: results of the 1998/1999 proficiency testing in Italy. SMIRA (Italian Multicentre Study on Antituberculosis Drug Resistance) Study Group.
,
2000,
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[6]
G. Migliori,et al.
Evaluation of tuberculosis treatment results in Italy, report 1998. Tuberculosis section of the National AIPO Study Group on Infectious Disease and the SMIRA Group.
,
2000,
Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.
[7]
M. Gismondo,et al.
Multicenter Evaluation of the Mycobacteria Growth Indicator Tube for Testing Susceptibility of Mycobacterium tuberculosis to First-Line Drugs
,
1999,
Journal of Clinical Microbiology.
[8]
D. Wilkinson.
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)
,
1998
.
[9]
Mohammad Mustafizur Rahman,et al.
Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Laboratory Network: first round of proficiency testing.
,
1997,
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[10]
Lung Disease,et al.
Anti-tuberculosis drug resistance in the world : the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance
,
1997
.
[11]
K. Tyler,et al.
Herpes Simplex Virus Infection as a Cause of Benign Recurrent Lymphocytic Meningitis
,
1994,
Annals of Internal Medicine.
[12]
A. Kochi,et al.
Multidrug-resistant tuberculosis and its control.
,
1993,
Research in microbiology.
[13]
N. L. Goodman,et al.
Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens
,
1983,
Journal of clinical microbiology.